Mikashmi Kohli

List of Publications by Year
in descending order

19 papers	1,209 citations	623734 14 h-index	794594 19 g-index
19 all docs	19 docs citations	19 times ranked	1051 citing authors

#	Article	IF	Citations
1	Biomarkers That Correlate with Active Pulmonary Tuberculosis Treatment Response: a Systematic Review and Meta-analysis. Journal of Clinical Microbiology, 2022, 60, JCM0185921.	3.9	28
2	Most common reasons for primary care visits in low- and middle-income countries: A systematic review. PLOS Global Public Health, 2022, 2, e0000196.	1.6	9
3	Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2021, 2021, CD012768.	2.8	63
4	Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. The Cochrane Library, 2021, 2021, CD009593.	2.8	58
5	Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. The Cochrane Library, 2021, 2021, CD013694.	2.8	19
6	Extrapulmonary tuberculosis. Expert Review of Respiratory Medicine, 2021, 15, 931-948.	2.5	60
7	Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis. European Respiratory Journal, 2021, 57, 2000747.	6.7	16
8	The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet, The, 2021, 398, 1997-2050.	13.7	149
9	Advances in Molecular Diagnosis of Tuberculosis. Journal of Clinical Microbiology, 2020, 58, .	3.9	83
10	GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology, 2020, 122, 142-152.	5.0	167
11	Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of pulmonary tuberculosis. The Cochrane Library, 2020, , .	2.8	3
12	SARS-CoV-2 testing in low- and middle-income countries: availability and affordability in the private health sector. Microbes and Infection, 2020, 22, 511-514.	1.9	10
13	GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology, 2020, 122, 129-141.	5.0	168
14	Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. Gates Open Research, 2020, 4, 24.	1.1	33
15	Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers. Gates Open Research, 2020, 4, 24.	1.1	25
16	Urinary EPCR and dermcidin as potential novel biomarkers for severe adult OSA patients. Sleep Medicine, 2019, 64, 92-100.	1.6	4
17	Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2019, 6, CD009593.	2.8	144
18	Xpert^{Â®}MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. The Cochrane Library, 2018, 8, CD012768.	2.8	153

#	ARTICLE	IF	CITATIONS
19	Availability of essential diagnostics in primary care in India. Lancet Infectious Diseases, The, 2018, 18, 1064-1065.	9.1	17